Search This Blog

Thursday, August 3, 2023

Aravive phase 3 ovarian cancer trial topline misses

 

  • Trial did not meet primary endpoint of progression-free survival

  • Cash at the end of Q2 of approximately $18M (unaudited) is expected to be sufficient to fund operations into early Q4 2023

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)